Skip to main content

Table 2 Cohort size, person years and incident cases of breast cancer subtypes across five-year age bands.

From: Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study

  Age bands
  ≤ 49 years 50-54 years 55-59 years 60-64 years ≥ 65 years All women
Subjects at risk 141513 175268 185404 161850 113810 314670
Person years 870491 627875 661652 565289 673872 3399178
Total cases 1 1205 (12.6%) 1770 (18.6%) 2151 (22.6%) 2065 (21.7%) 2339 (24.5%) 9530
ER-positive 507 (8.8%) 1031 (17.9%) 1402 (24.3%) 1345 (23.3%) 1479 (25.7%) 5764
ER-negative 235 (16.7%) 306 (21.7%) 320 (22.7%) 294 (20.9%) 255 (18.1%) 1410
ER-missing 463 (19.7%) 433 (18.4%) 429 (18.2%) 426 (18.1%) 605 (25.7%) 2356
PR-positive 462 (12.1%) 755 (19.8%) 872 (22.9%) 839 (22.0%) 880 (23.1%) 3808
PR-negative 212 (10.0%) 397 (18.8%) 553 (26.2%) 499 (23.6%) 453 (21.4%) 2114
PR-missing 531 (14.7%) 618 (17.1%) 726 (20.1%) 727 (20.1%) 1,006 (27.9%) 3608
ER+PR+ 390 (10.9%) 698 (19.5%) 830 (23.1%) 806 (22.5%) 862 (24.0%) 3586
ER+PR- 64 (5.9%) 180 (16.6%) 306 (28.2%) 280 (25.8%) 256 (23.6%) 1086
ER-PR+ 71 (33.3%) 57 (26.8%) 37 (17.4%) 31 (14.6%) 17 (8.0%) 213
ER-PR- 147 (14.4%) 217 (21.3%) 244 (23.9%) 217 (21.3%) 196 (19.2%) 1021
ER or PR missing 533 (14.7%) 618 (17.1%) 734 20.3% 731 (20.2%) 1008 (27.8%) 3624
  1. 1Including women of unknown receptor status. ER, estrogen receptor; PR, progesterone receptor.